Cited 2 times since 2023 (1 per year) source: EuropePMC JCO precision oncology, Volume 7, 1 1 2023, Pages e2300451 Efficacy and Tolerability of Osimertinib and Sotorasib Combination Treatment for Osimertinib Resistance Caused by <i>KRAS</i> G12C Mutation: A Report of Two Cases. Ernst SM, Uzun S, Paats MS, van Marion R, Atmodimedjo PN, de Jonge E, van Schaik RHN, Aerts JGJV, von der Thüsen JH, Dubbink HJ, Dingemans AC